BEIJING, Dec. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. , a leading provider of vaccines in China, today announced that it has scheduled a conference call on Thursday, December 13, 2007 at 9:00 a.m. E.T. (10:00 p.m. Beijing time) to review the unaudited financial results for the three months ended September 30, 2007. Mr. Weidong Yin, Chairman, President and CEO, will host the conference call.
The conference call dial-in numbers are 1-877-407-4018 (USA) or 1-201-689- 8471 (International). A dial-up replay of the conference call will be available beginning December 13, 2007 following the call and ending on December 27, 2007. The replay telephone number is 1-877-660-6853 (USA) or 1- 201-612-7415 (International), Account Number: 3055, Conference ID Number: 265872. A live web cast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A web cast replay can be accessed on the corporate web site beginning December 13, 2007. The replay will remain available until January 10, 2007.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac’s vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
info@sinovac.comscarrington@theruthgroup.com / jmccargo@theruthgroup.com
CONTACT: Helen G. Yang of Sinovac Biotech Ltd., +86-10-82890088 x871, or
fax, +86-10-62966910, or info@sinovac.com; or Stephanie Carrington/Janine
McCargo, all of The Ruth Group for Sinovac Biotech Ltd.,
+1-646-536-7017/7033, or scarrington@theruthgroup.com, or
jmccargo@theruthgroup.com
Web site: http://www.sinovac.com/
